Application of lactyltransferase inhibitor in pancreatic cancer and immunotherapy thereof

By using a composition of histone lactoyl transferase inhibitor and anti-programmed death receptor-1 antibody in pancreatic cancer treatment, the problem of limited efficacy and immunosuppressive microenvironment in pancreatic cancer treatment was solved, and significant anti-tumor effect and extended survival time were achieved.

CN119679939AActive Publication Date: 2025-03-25南昌大学第一附属医院
7 Cites 2 Cited by

Patent Information

Application Number
CN202510200544.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-02-24
Publication Date
2025-03-25
Estimated Expiration
2045-02-24

AI Technical Summary

Technical Problem

The prior art has limited efficacy, severe side effects and limitations of the immunosuppressive microenvironment in the treatment of pancreatic cancer, resulting in high mortality and high recurrence of pancreatic cancer.

Method used

The composition of histone lactoyl transferase inhibitor and anti-programmed death receptor-1 antibody is used to reduce the infiltration level of tumor neutrophils and increase the infiltration level of CD8-positive T cells, and reverse the inhibitory immune microenvironment of pancreatic cancer.

Benefits of technology

It significantly enhances the identification and removal of cancer cells by the immune system, effectively inhibits the growth of pancreatic cancer tumors, prolongs the survival time of patients, reduces the side effects of treatment, and improves the quality of life.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of cancer treatment, and provides application of a lactyltransferase inhibitor in pancreatic cancer and immunotherapy thereof. According to the present invention, the histone lactosyltransferase inhibitor and the anti-programmed death receptor-1 antibody are combined to form the composition for pancreatic cancer and immunotherapy thereof, such that the recognition and the removal of the immune system on the cancer cells can be enhanced, the growth of the pancreatic cancer tumor can be effectively inhibited, and the survival time of the pancreatic cancer patient can be prolonged. The histone lactosyltransferase inhibitor reduces the infiltration level of tumor-associated neutrophil, increases the infiltration level of CD8 positive T cells, reverses the composition of a pancreatic cancer inhibitory immune microenvironment, and generates a synergistic anti-tumor effect with an anti-programmed death receptor-1 antibody. The traditional Chinese medicine composition is suitable for early-stage, middle-stage and late-stage treatment of pancreatic cancer, improves the survival rate and the treatment effect of pancreatic cancer patients, remarkably reduces the side effects of treatment and improves the living quality of the pancreatic cancer patients.
Need to check novelty before this filing date? Find Prior Art